| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 355 | 2021 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 298 | 2020 |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology WG Wierda, JC Byrd, JS Abramson, SF Bilgrami, G Bociek, D Brander, ... Journal of the National Comprehensive Cancer Network 18 (2), 185-217, 2020 | 125 | 2020 |
| Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies P Ghione, JJ Gu, K Attwood, P Torka, S Goel, S Sundaram, C Mavis, ... Blood, The Journal of the American Society of Hematology 138 (9), 811-814, 2021 | 98 | 2021 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 89 | 2021 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
| Burkitt lymphoma international prognostic index AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, ... Journal of clinical oncology 39 (10), 1129-1138, 2021 | 59 | 2021 |
| Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature H Haddad, S Sundaram, C Magro, U Gergis Hematology/oncology and stem cell therapy 7 (2), 90-92, 2014 | 49 | 2014 |
| Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics P Torka, SK Kothari, S Sundaram, S Li, LJ Medeiros, EC Ayers, ... Blood advances 4 (2), 253-262, 2020 | 34 | 2020 |
| HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis JP Alderuccio, AJ Olszewski, AM Evens, GP Collins, AV Danilov, M Bower, ... Blood advances 5 (14), 2852-2862, 2021 | 33 | 2021 |
| Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma AR Singh, JJ Gu, Q Zhang, P Torka, S Sundaram, C Mavis, ... Cancer & Metabolism 8, 1-13, 2020 | 29 | 2020 |
| Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study AS Zayac, AM Evens, A Danilov, SD Smith, D Jagadeesh, LA Leslie, ... Haematologica 106 (7), 1932, 2021 | 28 | 2021 |
| Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study AR Mato, JM Pagel, CC Coombs, NN Shah, N Lamanna, T Munir, ... Blood 138, 391, 2021 | 19 | 2021 |
| Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma‐specific venous thrombosis prediction models G Dharmavaram, S Cao, S Sundaram, S Ayyappan, K Boughan, ... American journal of hematology 95 (8), 918-926, 2020 | 18 | 2020 |
| MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study JB Cohen, NN Shah, AJ Alencar, JN Gerson, MR Patel, B Fakhri, ... Clinical Lymphoma Myeloma and Leukemia 22, S394-S395, 2022 | 14 | 2022 |
| Outcomes of patients with newly-diagnosed Burkitt lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: A multi-institutional real-world analysis A Zayac, AM Evens, A Stadnik, SD Smith, D Jagadeesh, LA Leslie, C Wei, ... Blood 134, 402, 2019 | 14 | 2019 |
| Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study M Wang, NN Shah, AJ Alencar, JN Gerson, MR Patel, B Fakhri, W Jurczak, ... Blood 138, 381, 2021 | 13 | 2021 |
| Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era–tissue remains the issue S Sundaram, M Jizzini, D Lamonica, K Attwood, M Gravina, ... Leukemia & lymphoma 61 (13), 3226-3233, 2020 | 11 | 2020 |
| Safety and efficacy of tenalisib given in combination with Romidepsin in patients with relapsed/refractory T-cell lymphoma: final results from a phase I/II open label multi … SP Iyer, A Huen, WZ Ai, D Jagadeesh, MJ Lechowicz, C Okada, ... Blood 138, 1365, 2021 | 10 | 2021 |
| Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large … P Torka, C Mavis, S Kothari, S Belliotti, J Gu, S Sundaram, M Barth, ... EJHaem 1 (1), 122-132, 2020 | 10 | 2020 |
